Eleni‐Kyriaki Vetsika

Author

Also Known As

A Vetsika, E K Vetsika, E Vetsika, E-K Vetsika, E. -K. Vetsika, E.-K. Vetsika, E.K. Vetsika, EK Vetsika, ELENI-KYRIAKI VETSIKA, Eleni Kyriaki Vetsika

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Crete University Hospital of Heraklion University Hospital of Larissa Hellenic Oncology Research Group IASO General Hospital

About

Eleni‐Kyriaki Vetsika is an author at University of Crete specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	348
2	Immunology	6	6	307
3	Pathology	4	4	159
4	Cell Biology	2	2	26
5	Pharmacology	1	1	31

Eleni‐Kyriaki Vetsika

Publications

721

Citations

H-Index

Page 1

	Year	Citations
A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients Eleni‐Kyriaki Vetsika, Filippos Koinis, Marianthi Gioulbasani, Journal of Immunology Research	2014	118
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer Filippos Koinis, Eleni‐Kyriaki Vetsika, Despoina Aggouraki, Journal of Thoracic Oncology Hematological MalignancyTumor BiologyMedicineImmunologyPathology	2016	98
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients Αthanasios Kotsakis, Filippos Koinis, Afroditi Katsarou, Scientific Reports	2016	95
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer Galatea Kallergi, Eleni‐Kyriaki Vetsika, Despoina Aggouraki, Therapeutic Advances in Medical Oncology	2018	71
A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide Αthanasios Kotsakis, E. Papadimitraki, Eleni‐Kyriaki Vetsika, Lung Cancer VaccinationHtert Cryptic PeptideCancer ImmunosurveillancePhase Ii TrialMedicine	2014	64
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study Eleni‐Kyriaki Vetsika, Soultana Christou, Dora Hatzidaki, Annals of Oncology Clinical OutcomeOncologyReverse VaccinologyMedicineImmunology	2011	50
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001 Eleni‐Kyriaki Vetsika, Georgios Konsolakis, Despoina Aggouraki, Cancer Immunology Immunotherapy VaccinationTumor ImmunologyCancer ImmunosurveillanceImmunologyTumor Immunity	2011	44
Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment Ippokratis Messaritakis, Fillipos Koinis, Eleni Politaki, Lung Cancer Tumor BiologyMedicineImmunologyClinical RelevancePathology	2019	35
The effect of substance P on nitric oxide release in a rheumatoid arthritis model Meg C. O'Shaughnessy, Eleni‐Kyriaki Vetsika, Julia J. Inglis, Inflammation Research InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryNitric Oxide Release	2006	31
Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients Maria A. Papadaki, Despoina Aggouraki, Eleni‐Kyriaki Vetsika, Anticancer Research	2021	20

Page 1